Associations of Trimethylamine N-Oxide With Nutritional and Inflammatory Biomarkers and Cardiovascular Outcomes in Patients New to Dialysis

Journal of Renal Nutrition

Volumn 25, Issue 4, 2015, Pages 351-356

  Kaysen, George A ^a,b   Johansen, Kirsten L ^c,d   Chertow, Glenn M ^e   Dalrymple, Lorien S ^a   Kornak, John ^d   Grimes, Barbara ^d   Dwyer, Tjien ^a   Chassy, Alexander W ^a   Fiehn, Oliver ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; METHYLAMINE; TRIMETHYLOXAMINE;

BLOOD; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; FEMALE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; INFLAMMATION; KAPLAN MEIER METHOD; KIDNEY FAILURE, CHRONIC; LIQUID CHROMATOGRAPHY; MALE; MIDDLE AGED; MORTALITY; NUTRITIONAL STATUS; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TANDEM MASS SPECTROMETRY;

BIOMARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHROMATOGRAPHY, LIQUID; COHORT STUDIES; COMORBIDITY; FEMALE; HOSPITALIZATION; HUMANS; INFLAMMATION; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; METHYLAMINES; MIDDLE AGED; NUTRITIONAL STATUS; RENAL DIALYSIS; RISK FACTORS; TANDEM MASS SPECTROMETRY;

EID: 84930824245     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2015.02.006     Document Type: Article

References (29)

1. Koeth R.A., Wang Z., Levinson B.S., et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat. Promotes Atherosclerosis Nat Med 2013, 19:576-585.
2. Wang Z., Klipfell E., Bennett B.J., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472:57-63.
3. Lambert D.M., Mamer O.A., Akerman B.R., et al. Invivo variability of TMA oxidation is partially mediated by polymorphisms of the FMO3 gene. Mol Genet Metab 2001, 73:224-229.
4. Tang W.H., Wang Z., Levison B.S., et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013, 368:1575-1584.
5. Simenhoff M.L., Burke J.F., Saukkonen J.J., Ordinario A.T., Doty R. Biochemical profile or uremic breath. N Engl J Med 1977, 297:132-135.
6. Bain M.A., Faull R., Fornasini G., Milne R.W., Evans A.M. Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrol Dial Transplant 2006, 21:1300-1304.
7. Tang W.W., Wang Z., Kennedy D.J., et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 2015, 116:448-455.
8. Anders H.J., Andersen K., Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int 2013, 83:1010-1016.
9. Vitetta L., Gobe G. Uremia and chronic kidney disease: the role of the gut microflora and therapies with pro- and prebiotics. Mol Nutr Food Res 2013, 57:824-832.
10. de la Huerga J., Popper H. Urinary excretion of choline metabolites following choline administration in normals and patients with hepatobiliary diseases. J Clin Invest 1951, 30:463-470.
11. Ihle B.U., Cox R.W., Dunn S.R., Simenhoff M.L. Determination of body burden of uremic toxins. Clin Nephrol 1984, 22:82-89.
12. Simenhoff M.L., Saukkonen J.J., Burke J.F., Wesson L.G., Schaedler R.W. Amine metabolism and the small bowel in uraemia. Lancet 1976, 2:818-821.
13. Kutner N.G., Johansen K.L., Kaysen G.A., et al. The Comprehensive Dialysis Study (CDS): a USRDS special study. Clin J Am Soc Nephrol 2009, 4:645-650.
14. Anand S., Chertow G.M., Johansen K.L., et al. Association of self-reported physical activity with laboratory markers of nutrition and inflammation: the Comprehensive Dialysis Study. J Ren Nutr 2011, 21:429-437.
15. Gai Z., Chu L., Hiller C., et al. Effect of chronic renal failure on the hepatic, intestinal, and renal expression of bile acid transporters. Am J Physiol Renal Physiol 2014, 306:F130-F137.
16. Vaziri N.D., Sato T., Liang K. Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis. Kidney Int 2003, 63:1756-1763.
17. Hedayati S.S. Dialysis-related carnitine disorder. Semin Dial 2006, 19:323-328.
18. Ahmad S. L-Carnitine in dialysis patients. Semin Dial 2001, 14:209-217.
19. Hurot J.M., Cucherat M., Haugh M., Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 2002, 13:708-714.
20. Chen Y., Abbate M., Tang L., et al. L-Carnitine supplementation for adults with end-stage kidney disease requiring maintenance hemodialysis: a systematic review and meta-analysis. Am J Clin Nutr 2014, 99:408-422.
21. Lowrie E.G., Lew N.L. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990, 15:458-482.
22. Liu Y., Coresh J., Eustace J.A., et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004, 291:451-459.
23. Kwan B.C., Kronenberg F., Beddhu S., Cheung A.K. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 2007, 18:1246-1261.
24. Mekki K., Bouchenak M., Lamri M., Remaoun M., Belleville J. Changes in plasma lecithin: cholesterol acyltransferase activity, HDL(2), HDL(3) amounts and compositions in patients with chronic renal failure after different times of hemodialysis. Atherosclerosis 2002, 162:409-417.
25. Mekki K., Bouchenak M., Remaoun M., Belleville J.L. Effect of long-term hemodialysis on plasma lecithin: cholesterol acyltransferase activity and the amounts and compositions of HDL2 and HDL3 in hemodialysis-treated patients with chronic renal failure: a 9-year longitudinal study. Med Sci Monit 2004, 10:CR439-CR446.
26. Mangé A., Goux A., Badiou S., et al. HDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatography-tandem mass spectrometry approach. PLoS One 2012, 7:e34107.
27. Kaysen G.A., Greene T., Daugirdas J.T., et al. Longitudinal and cross-sectional effects of C-reactive protein, equilibrated normalized protein catabolic rate, and serum bicarbonate on creatinine and albumin levels in dialysis patients. Am J Kidney Dis 2003, 42:1200-1211. HEMO Study Group.
28. Kaysen G.A., Chertow G.M., Adhikarla R., Young B., Ronco C., Levin N.W. Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int 2001, 60:333-340.
29. Molfino A., Heymsfield S.B., Zhu F., et al. Prealbumin is associated with visceral fat mass in patients receiving hemodialysis. J Ren Nutr 2013, 23:406-410.